Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AAA

Ratings ESG MSCI

Ratings Hangzhou Tigermed Consulting Co., Ltd: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Hangzhou Tigermed Consulting Co., Ltd
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Hangzhou Tigermed Consulting Co., Ltd
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • Low profitability weakens the company.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Hangzhou Tigermed Consulting Co., Ltd SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Hangzhou Tigermed Consulting Co., Ltd SectorChina

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Hangzhou Tigermed Consulting Co., Ltd SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Hangzhou Tigermed Consulting Co., Ltd SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Hangzhou Tigermed Consulting Co., Ltd SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
6.51B
AAA
42.78B
AAA
31.5B -
29.99B
A
27.65B
AAA
18.8B -
B
- -
13.87B - -
12.78B
BBB
12.39B
AA
11.76B -
A
- -
Average 20.8B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. 300347 Stock
  4. Ratings Hangzhou Tigermed Consulting Co., Ltd
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW